medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-19-76-79medsovet-811Research ArticleПрактикаPracticeВлияние тадалафила на восстановление удержания мочи после нервосберегающей робот-ассистированной радикальной простатэктомииEffects of tadalafil on urinary continence recovery after nerve-sparing robot-assisted radical prostatectomyГоворовА. В.GovorovAVnoemail@neicon.ruПушкарьД. Ю.PushkarDYnoemail@neicon.ruВасильевА. О.VasilyevAOnoemail@neicon.ruПриймакД. В.PriymakDVnoemail@neicon.ruМосковский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииРоссияUrology department, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russia’s Ministry of HealthRussian Federation2014301220140197679Copyright © Говоров А.В., Пушкарь Д.Ю., Васильев А.О., Приймак Д.В., 20142014Говоров А.В., Пушкарь Д.Ю., Васильев А.О., Приймак Д.В.Govorov A., Pushkar D., Vasilyev A., Priymak D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/811

Ингибиторы фосфодиэстеразы 5-го типа (ФДЭ5) модулируют активность афферентных нервных волокон, повышают активность оксида азота, приводя тем самым к расслаблению гладкой мускулатуры кавернозных тел полового члена, простаты, уретры и шейки мочевого пузыря. Согласно Guidelines Европейской ассоциации урологов, применение ингибиторов ФДЭ5 снижает выраженность умеренных и тяжелых симптомов нарушенного мочеиспускания у мужчин как с эректильной дисфункцией (ЭД), так и без нее. Обзор современной литературы, посвященный применению ингибиторов ФДЭ5, показал, что в клинической практике препараты данной группы могут быть использованы не только при лечении ЭД, но и в терапии симптомов нижних мочевых путей (СНМП) у больных с доброкачественной гиперплазией предстательной железы, а также у пациентов с СНМП после перенесенной радикальной простатэктомии. Цель нашего исследования заключалась в оценке роли тадалафила в восстановлении удержания мочи у пациентов после проведения билатеральной нервосберегающей роботизированной радикальной простатэктомии (билатеральной НСРРПЭ).

Phosphodiesterase type 5 (PDE5) inhibitors modulate afferent nerve activity, increase nitric oxide activity resulting in the corpus cavernosal smooth muscle relaxation in the penis, prostate, urethra and bladder neck. According the European Urological Association guidelines, PDE5 inhibitors reduce the severity of moderate to severe symptoms of impaired urination in men with and without erectile dysfunction (ED). An overview of recent literature on the use of PDE5 inhibitors showed that they can be used clinically in the treatment of erectile dysfunction as well as in the therapy of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia and in patients with LUTS after radical prostatectomy. The aim of our study was to evaluate the role of tadalafil in restoring continence in patients after bilateral nerve-sparing robotic radical prostatectomy (bilateral NSRRPE).

ингибиторы ФДЭ5симптомы нижних мочевых путейэректильная дисфункциябилатеральная нервосберегающая роботизированная радикальная про-статэктомиятадалафилPDE5 inhibitorslower urinary tract symptomserectile dysfunctionbilateral nerve-sparing robotic radical prostatectomytadalafilReferencesChapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol., 2006, Apr, 49 (4): 651-658.Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol., 2006, Apr, 49 (4): 651-658.Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT. et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol., 2013, 5: 99-111.Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT. et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol., 2013, 5: 99-111.Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med., 2012, Jan, 9 (1): 265-270.Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med., 2012, Jan, 9 (1): 265-270.Cantrell M.A., Baye J., Vouri S.M. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy, 2013, Jun, 33 (6): 639-649. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013, 64 (1): 118-140.Cantrell M.A., Baye J., Vouri S.M. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy, 2013, Jun, 33 (6): 639-649. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013, 64 (1): 118-140.Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S. et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med, 2010, 7 (1): 234-243.Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S. et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med, 2010, 7 (1): 234-243.Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2012, 61: 994-1003.Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2012, 61: 994-1003.Gandaglia G, Suardi N, Gallina A, Capitanio U, Abdollah F, Salonia A. et al. Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. J Urol., 2012, 187 (2): 569-574.Gandaglia G, Suardi N, Gallina A, Capitanio U, Abdollah F, Salonia A. et al. Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. J Urol., 2012, 187 (2): 569-574.

The authors declare that there are no conflicts of interest present.